Activity Preview

Live

Using Biomarkers to Select Treatments: An Illustration From the International Study to Predict Optimized Treatment for Depression (ISPOT-D)

Activity Type:

  • On Demand


Release Date: 8/20/2015

Expiration Date: 8/20/2018

  • AMA PRA Category 1: 1.5
  • Participation: 1.5

Access Activity

Overview

This course updates results in the ongoing International Study to Predict Optimized Treatment in Depression (iSPOT-D) that aims to identify practical, pretreatment measures to help select among three commonly prescribed antidepressants: escitalopram, sertraline or venlafaxine-XR. iSPOT-D mirrors routine practice while employing standardized pretreatment and post-treatment clinical and biological assessments in an 8 week randomized, 22 site acute treatment trial with up to a 44 week follow up.Specific allelic variation for MDR-1 predicts likelihood of remission in subgroups of subjects. Pretreatment behavioral measures of emotional identification, decision speed, attention and working memory were significant predictors of remission, independent of symptom severity. Further, interactions among performance on cognitive and emotional measures and genetic variation predicted outcome. A corresponding profile of limbic hyper-reactivity to emotional stimuli and frontal hypo-activity to cognitive and emotional tasks was revealed by functional neuroimaging.

**This content was captured at the 2014 APA Annual Meeting

Pricing

  • General Member - $22.50
  • Resident-Fellow Member - Free
  • Medical Student Member - $22.50
  • Non-Member - $45.00

Educational Objectives

  • Understand the design, rationale and clinical outcomes of the first 1008 iSPOT-D trial participants 
  • Recognize the clinical factors that predict treatment outcomes for depressed outpatients, including age of onset and anxiety 
  • Identify the genomic of response, particularly applying MDR-1 genotypes
  • Understand the behavioral and cognitive tests that may predict which medication to select in the acute treatment of depression
  • Appreciate combining data across classes of markers to predict response

Target Audience

Residents/Fellows and Psychiatrists

Estimated Time to Complete

1.5 Hours

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course including the evaluation. A multiple choice quiz is provided based on the content. A passing score of 60% must be achieved. Retakes are available for the test. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate showing the date of completion and hours earned. 

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Chairs:

  • Alan F. Schatzberg, M.D., Stanford University School of Medicine | Disclosure: Consultant/Advisory Board - Cenerx | Eli Lilly and Company | Gilead Sciences | Lundbeck | Merck & Co. | Neuronetics Inc. | PharmaNeuroBoost | Cervel Neurotech, Inc. | Genentech | Speakers Bureau/Speaker Honoraria - Merck & Co. | Stock/Other financial relationship - Brain Cells Inc. | Corcept Therapeutics, Inc. | Delpor Technology | Forest Laboratories, Inc. | Merck & Co. | Neurocrine Biosciences Inc. | Pfizer | Cervel Neurotech, Inc. | Consultants: Bay City Capital, McKinsey, MSI, and Xhale Equity: Amnestix and Xhale
  • Leanne Williams, Ph.D., Stanford University School of Medicine | Disclosure: Consultant/Advisory Board - Brain Resource Ltd. | Grant/Research Support - Brain Resource Ltd. | Stock/Other financial relationship - Brain Resource Ltd. 

Presenters:

  • Radu V. Saveanu, M.D., University of Miami School of Medicine | Disclosure: Grant/Research Support - Brain Resource Ltd.
  • Alan F. Schatzberg, M.D., Stanford University School of Medicine | Disclosure: Consultant/Advisory Board - Cenerx | Eli Lilly and Company | Gilead Sciences | Lundbeck | Merck & Co. | Neuronetics Inc. | PharmaNeuroBoost | Cervel Neurotech, Inc. | Genentech | Speakers Bureau/Speaker Honoraria - Merck & Co. | Stock/Other financial relationship - Brain Cells Inc. | Corcept Therapeutics, Inc. | Delpor Technology | Forest Laboratories, Inc. | Merck & Co. | Neurocrine Biosciences Inc. | Pfizer | Cervel Neurotech, Inc. | Consultants: Bay City Capital, McKinsey, MSI, and Xhale Equity: Amnestix and Xhale
  • Leanne Williams, Ph.D., Stanford University School of Medicine | Disclosure: Consultant/Advisory Board - Brain Resource Ltd. | Grant/Research Support - Brain Resource Ltd. | Stock/Other financial relationship - Brain Resource Ltd.        

Program Planners:

  • Tristan Gorrindo, M.D., Director of Education, American Psychiatric Association | Disclsoure: Reports no financial relationships with commercial interests
  • Ricardo Juarez, Associate Director, Office of International Affairs, American Psychiatric Association | Disclosure: Reports no financial relationships with commercial interests

Hardware/Software Requirements

Hardware/Software Specifications:
This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements:
Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh:
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

For assistance: Contact educme@psych.org for questions about this course | Contact learningcenter@psych.org for technical assistance

Access Activity